{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:04:38Z","timestamp":1793815478711,"version":"4.6.1"},"reference-count":343,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jconrel.2022.01.044","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:10:22Z","timestamp":1643627422000},"page":"528-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"343","author":[{"given":"Rajeev","family":"Taliyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violina","family":"Kakoty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Sarathlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanskruti Santosh","family":"Kharavtekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekar R.","family":"Karennanavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra Kumar","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Riadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Kumar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.01.044_bb0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuropharm.2016.01.025","article-title":"Epigenetic modifications by inhibiting histone deacetylases reverse memory impairment in insulin resistance induced cognitive deficit in mice","volume":"105","author":"Sharma","year":"2016","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0015","first-page":"91","article-title":"Alzheimer\u2019s disease, Dialogues","volume":"2","author":"Schachter","year":"2000","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0020","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2174\/1381612825666190716101411","article-title":"Therapeutic approaches to Alzheimer\u2019s type of dementia: a focus on FGF21 mediated neuroprotection","volume":"25","author":"Taliyan","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12640-020-00258-1","article-title":"Exploring the neuroprotective potential of rosiglitazone embedded nanocarrier system on streptozotocin induced mice model of Alzheimer\u2019s disease","volume":"39","author":"Kakoty","year":"2021","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110145","article-title":"Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease","volume":"127","author":"Kakoty","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105008","article-title":"Biomaterials in treatment of Alzheimer\u2019s disease","volume":"145","author":"Agrawal","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0040","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.1997.03550160083043","article-title":"Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer\u2019s Association, and the American Geriatrics Society","volume":"278","author":"Small","year":"1997","journal-title":"JAMA"},{"issue":"2021","key":"10.1016\/j.jconrel.2022.01.044_bb0045","first-page":"327","article-title":"2021 Alzheimer\u2019s disease facts and figures","volume":"17","author":"A.A.","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0055","series-title":"M. Singh, M.B.T.-N.A. and S. for B. Salnikova Vaccines and Cancer Therapies (Eds.)","first-page":"41","article-title":"Chapter 3 - Advances in nanotechnology-based drug delivery platforms and novel drug delivery systems","author":"Suri","year":"2015"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0060","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s13346-018-0552-2","article-title":"Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends","volume":"8","author":"Choudhury","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jddst.2017.09.022","article-title":"Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders","volume":"43","author":"Md","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0070","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.drudis.2016.02.006","article-title":"Dendrimer technologies for brain tumor","volume":"21","author":"Mishra","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0075","doi-asserted-by":"crossref","first-page":"2003054","DOI":"10.1002\/adfm.202003054","article-title":"Recent advancements of nanomedicine in neurodegenerative disorders theranostics","volume":"30","author":"Mukherjee","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0080","first-page":"307","article-title":"Micelle-based drug delivery for brain tumors, nanotechnology-based target","author":"Gothwal","year":"2018","journal-title":"Drug Deliv. Syst. Brain Tumors."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120351","article-title":"Evolving new-age strategies to transport therapeutics across the blood-brain-barrier","author":"Choudhari","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135865","article-title":"The gut-brain connection in the pathogenicity of Parkinson disease: putative role of autophagy","volume":"753","author":"Kakoty","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0095","series-title":"Theory Appl. Nonparenteral Nanomedicines","first-page":"153","article-title":"From the nose to the brain, nanomedicine drug delivery","author":"Zeeshan","year":"2021"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jscs.2012.12.009","article-title":"Advanced drug delivery systems: nanotechnology of health design A review","volume":"18","author":"Safari","year":"2014","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0105","series-title":"Controlled Release and Nanotechnology BT - Nanotechnology in Drug Delivery","first-page":"283","author":"Betancourt","year":"2009"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09205063.2015.1133155","article-title":"Dendrimer-mediated approaches for the treatment of brain tumor","volume":"27","author":"Dwivedi","year":"2016","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcis.2016.07.047","article-title":"Ligand anchored poly(propyleneimine) dendrimers for brain targeting: comparative in vitro and in vivo assessment","volume":"482","author":"Patel","year":"2016","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","article-title":"Stimuli-responsive In situ gelling system for nose-to-brain drug delivery","volume":"327","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fbioe.2021.630055","article-title":"Nanomedicine: a promising way to manage Alzheimer\u2019s disease","volume":"9","author":"Khan","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0130","doi-asserted-by":"crossref","first-page":"89040","DOI":"10.1039\/C6RA17290C","article-title":"Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors","volume":"6","author":"Kesharwani","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0135","first-page":"267","article-title":"Dendrimers as effective carriers for the treatment of brain tumor, nanotechnology-based target","author":"Gorain","year":"2018","journal-title":"Drug Deliv. Syst. Brain Tumors."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0140","first-page":"375","article-title":"Carbon nanotubes (CNTs): a novel drug delivery tool in brain tumor treatment, nanotechnology-based target","author":"Meher","year":"2018","journal-title":"Drug Deliv. Syst. Brain Tumors."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0145","doi-asserted-by":"crossref","DOI":"10.2174\/1381612826666200313125613","article-title":"Nose to brain delivery of nanocarriers towards attenuation of demented condition","volume":"26","author":"Gorain","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0150","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2174\/1567205014666170203125942","article-title":"Biomarkers for Alzheimer\u2019s Disease Diagnosis","volume":"14","author":"Mantzavinos","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0155","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer\u2019s disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0160","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acschemneuro.1c00022","article-title":"Neuroprotective efficacy of co-encapsulated rosiglitazone and vorinostat nanoparticle on streptozotocin induced mice model of Alzheimer disease","volume":"12","author":"Kakoty","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0039-1681041","article-title":"Alzheimer\u2019s disease including focal presentations","volume":"39","author":"Villain","year":"2019","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0170","series-title":"Encycl. Neurol. Biosci","first-page":"122","article-title":"Alzheimer\u2019s disease","author":"Pressman","year":"2014"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0175","series-title":"Epigenetic Regulation of Mammalian Target of Rapamycin Debilitates Insulin Resistance Associated Alzheimer Disease Condition in Rats","author":"Kakoty","year":"2021"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0180","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease, Alzheimer\u2019s & Dement","volume":"4","author":"Kinney","year":"2018","journal-title":"Transl. Res. Clin. Interv"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015746","article-title":"Signs and symptoms preceding the diagnosis of Alzheimer\u2019s disease: a systematic scoping review of literature from 1937 to 2016","volume":"7","author":"Bature","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0190","series-title":"Alzheimer\u2019s Disease Facts and Figures 2016","first-page":"459","year":"2016"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0195","doi-asserted-by":"crossref","first-page":"P657","DOI":"10.1016\/j.jalz.2017.06.780","article-title":"AR-A014418, A GSK-3\u03b2 inhibitor, attenuates Alzheimer\u2019s- like pathology in high fat diet-induced cognitive deficit in mice","volume":"13","author":"Sharma","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0200","series-title":"Alzheimer\u2019s disease: clinical update on epidemiology, pathophysiology and diagnosis","first-page":"347","volume":"26","author":"Eratne","year":"2018"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5114\/fn.2019.85929","article-title":"Risk factors for Alzheimer\u2019s disease","volume":"57","author":"Armstrong","year":"2019","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0215","article-title":"Head injury as a risk factor for dementia and Alzheimer\u2019s disease: a systematic review and meta-analysis of 32 observational studies","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2022.01.044_bb0220","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.3233\/JAD-2010-100501","article-title":"Why women have more Alzheimer\u2019s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide","volume":"20","author":"Vi\u00f1a","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/YCO.0000000000000401","article-title":"Sex differences in Alzheimer\u2019s disease","volume":"31","author":"Laws","year":"2018","journal-title":"Curr. Opin. Psychiatry."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0230","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.bbrc.2014.09.034","article-title":"Neuroprotective role of Indirubin-3\u2019-monoxime, a GSK\u03b2 inhibitor in high fat diet induced cognitive impairment in mice","volume":"452","author":"Sharma","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0235","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fnagi.2015.00130","article-title":"Menopause, obesity and inflammation: interactive risk factors for Alzheimer\u2019s disease","volume":"7","author":"Christensen","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2011.06274.x","article-title":"Obesity, leptin, and Alzheimer\u2019s disease","volume":"1243","author":"Lee","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12031-014-0461-x","article-title":"Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice","volume":"56","author":"Sharma","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbr.2018.05.025","article-title":"High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats","volume":"351","author":"Sharma","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0255","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11910-020-01090-y","article-title":"Early-onset Alzheimer\u2019s disease: what is missing in research?","volume":"21","author":"Ayodele","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","article-title":"On the path to 2025: understanding the Alzheimer\u2019s disease continuum","volume":"9","author":"Aisen","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0265","first-page":"228","article-title":"Alzheimer\u2019s disease: early diagnosis and treatment","volume":"18","author":"Chu","year":"2012","journal-title":"Hong Kong Med. J. = Xianggang Yi Xue Za Zhi."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/fn.2013.34190","article-title":"Molecular mechanisms of neuropathological changes in Alzheimer\u2019s disease: a review","volume":"51","author":"Ser\u00fd","year":"2013","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0275","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0280","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0285","first-page":"353","volume":"297","author":"Hardy","year":"2002","journal-title":"J science Selkoe, The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0290","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-$\u03b2$ protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0295","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000358875","article-title":"Tau-based therapeutic approaches for Alzheimer\u2019s disease - a mini-review","volume":"60","author":"Boutajangout","year":"2014","journal-title":"Gerontology."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0300","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40265-015-0529-0","article-title":"Tau biology and Tau-directed therapies for Alzheimer\u2019s disease","volume":"76","author":"Bakota","year":"2016","journal-title":"Drugs."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","article-title":"Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer\u2019s disease","volume":"52","author":"Barage","year":"2015","journal-title":"Neuropeptides."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0310","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14283\/jpad.2018.43","article-title":"Revisiting the cholinergic hypothesis in Alzheimer\u2019s disease: emerging evidence from translational and clinical research","volume":"6","author":"Hampel","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0320","article-title":"Cognitive symptoms of Alzheimer\u2019s disease: clinical management and prevention","volume":"367","author":"Joe","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0330","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of Glutamate and NMDA receptors in Alzheimer\u2019s disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0335","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","article-title":"Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer\u2019s disease","volume":"45","author":"Hynd","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0340","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.2174\/0929867325666180221125759","article-title":"Current Limitations in the treatment of Parkinson\u2019s and Alzheimer\u2019s diseases: state-of-the-art and future perspective of polymeric carriers","volume":"25","author":"Tonda-Turo","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0345","article-title":"Aducanumab for Alzheimer\u2019s disease?","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0350","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/B978-0-12-387817-5.00040-6","article-title":"LiverTox: a website on drug-induced liver injury","author":"Hoofnagle","year":"2013","journal-title":"InDrug-Induced Liver Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0355","series-title":"The technologies, Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease, Guidance|","year":"2011"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0360","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0365","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3233\/JAD-130395","article-title":"Effectiveness and safety of memantine treatment for Alzheimer\u2019s disease","volume":"36","author":"Yang","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0370","series-title":"Geriatr. Neurol","first-page":"231","article-title":"Chapter 13 - Alzheimer\u2019s disease","year":"2019"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0375","first-page":"255","article-title":"Clinical development of aducanumab, an anti-A\u03b2 human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s disease","volume":"4","author":"Budd Haeberlein","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0380","first-page":"2589276","article-title":"Therapies for prevention and treatment of Alzheimer\u2019s disease","author":"Mendiola-Precoma","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/nnm.15.166","article-title":"Nanoparticle systems reduce systemic toxicity in cancer treatment","volume":"11","author":"Wang","year":"2016","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0395","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","article-title":"Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer\u2019s disease","volume":"25","author":"Karthivashan","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s40089-014-0094-7","article-title":"Nanomedicine and drug delivery: a mini review","volume":"4","author":"Mirza","year":"2014","journal-title":"Int. Nano Lett."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","article-title":"Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles","volume":"4","author":"Singh","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0415","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425240902758188","article-title":"Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases","volume":"6","author":"Barchet","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0420","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.23648","article-title":"The blood-brain barrier in health and disease","volume":"72","author":"Daneman","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0425","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0430","doi-asserted-by":"crossref","first-page":"12583","DOI":"10.1021\/acsomega.0c01592","article-title":"Nanocarriers as potential drug delivery candidates for overcoming the blood\u2013brain barrier: challenges and possibilities","volume":"5","author":"Ahlawat","year":"2020","journal-title":"ACS Omega."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0435","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0040-8166(86)90026-1","article-title":"The pericyte--a review","volume":"18","author":"Sims","year":"1986","journal-title":"Tissue Cell"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0440","first-page":"1031","article-title":"Pericyte physiology","volume":"7","author":"Shepro","year":"1993","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0445","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.devcel.2011.07.001","article-title":"Pericytes: developmental, physiological, and pathological perspectives, problems, and promises","volume":"21","author":"Armulik","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0450","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2045-8118-9-23","article-title":"Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation","volume":"9","author":"Luissint","year":"2012","journal-title":"Fluids Barriers CNS."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0455","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nm.1957","article-title":"Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain","volume":"15","author":"Wu","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0460","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/glia.20990","article-title":"The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction","volume":"58","author":"Mathiisen","year":"2010","journal-title":"Glia."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0465","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fncel.2018.00193","article-title":"Emerging roles of astrocytes in neuro-vascular unit and the tripartite synapse with emphasis on reactive gliosis in the context of Alzheimer\u2019s disease","volume":"12","author":"Liu","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0470","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","article-title":"The blood-brain barrier in Alzheimer\u2019s disease","volume":"107","author":"Zenaro","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0475","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbadis.2015.10.004","article-title":"Glial influences on BBB functions and molecular players in immune cell trafficking","volume":"1862","author":"L\u00e9cuyer","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0480","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrn3722","article-title":"Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease","volume":"15","author":"Prinz","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0485","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood\u2013brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0490","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2005.07.013","article-title":"Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier","volume":"108","author":"Costantino","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0495","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1073\/pnas.0509425103","article-title":"In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space","volume":"103","author":"Thorne","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0500","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2005.09.053","article-title":"Barriers to carrier mediated drug and gene delivery to brain tumors","volume":"110","author":"Huynh","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10717549809065759","article-title":"Serum proteins as drug carriers of anticancer agents: a review","volume":"5","author":"Kratz","year":"1998","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0510","doi-asserted-by":"crossref","first-page":"14352","DOI":"10.1016\/S0021-9258(18)47945-8","article-title":"Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain","volume":"262","author":"Pitas","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0515","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s11095-009-9964-5","article-title":"Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer","volume":"26","author":"Thomas","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0520","series-title":"The Role of Drug Transporters at the Blood Brain Barrier","author":"Sahi","year":"2016"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0525","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-409X(02)00172-2","article-title":"Drug efflux transporters in the CNS","volume":"55","author":"Sun","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0530","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1537-1891(02)00201-X","article-title":"Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier","volume":"38","author":"Demeule","year":"2002","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0540","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0169-409X(00)00104-6","article-title":"Microdialysis in the study of drug transporters in the CNS","volume":"45","author":"Sawchuk","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0545","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0550","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4155\/tde.10.58","article-title":"Delivering drugs into the brain: barriers and possibilities","volume":"1","author":"Habgood","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0555","doi-asserted-by":"crossref","first-page":"39","DOI":"10.29245\/2572.942X\/2018\/4.1194","article-title":"CHoroid plexus blood-CSF barrier: major player in brain modeling and neuromedicine","volume":"3","author":"J. CE","year":"2018","journal-title":"Neurol. Neuromed."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0560","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1083\/jcb.142.1.117","article-title":"Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration","volume":"142","author":"Mart\u00ecn-Padura","year":"1998","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6107(02)00037-8","article-title":"Tight junction proteins","volume":"81","author":"Gonz\u00e1lez-Mariscal","year":"2003","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0570","first-page":"146","article-title":"Formation of tight junction: determinants of homophilic interaction between classic claudins","volume":"22","author":"Piontek","year":"2008","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0575","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-8118-8-3","article-title":"Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences","volume":"8","author":"Redzic","year":"2011","journal-title":"Fluids Barriers CNS."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0580","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcpa.2015.08.009","article-title":"A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity of rats, mice, dogs and non-human primates. Relevance to inhalation toxicology and human health risk assessment","volume":"153","author":"Chamanza","year":"2015","journal-title":"J. Comp. Pathol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.044_bb0585","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fsc.2004.04.001","article-title":"Nasal anatomy and physiology","volume":"12","author":"Lane","year":"2004","journal-title":"Facial Plast. Surg. Clin. North Am"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0590","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.coms.2012.01.011","article-title":"Surgical anatomy of the nasal cavity and paranasal sinuses","volume":"24","author":"Ogle","year":"2012","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0595","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0600","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0605","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0610","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104795","article-title":"Nose to brain drug delivery - a promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion","volume":"159","author":"Long","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0620","first-page":"288","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci. a Publ. Can. Soc. Pharm. Sci. Soc. Can. Des Sci. Pharm"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the Nasal Olfactory Mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0630","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119491","article-title":"Nanomaterial-based blood-brain-barrier (BBB) crossing strategies","volume":"224","author":"Xie","year":"2019","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","volume":"570","author":"Martins","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0645","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i1.20","article-title":"Drug delivery to the nasal cavity: in vitro and in vivo assessment","volume":"21","author":"Newman","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0650","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0655","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijpharm.2019.05.032","article-title":"Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges","volume":"565","author":"Chatterjee","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0660","first-page":"2088","article-title":"Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting","volume":"46","author":"Selvaraj","year":"2018","journal-title":"Artif. Cells, Nanomedicine Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0665","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1166\/jbn.2019.2724","article-title":"The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: evidence from aggregation-caused quenching probes","volume":"15","author":"Li","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020095","article-title":"Mechanisms of intranasal deferoxamine in neurodegenerative and neurovascular disease","volume":"14","author":"Kosyakovsky","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0675","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0680","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0685","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017018693","article-title":"Lipid nanoparticles for nasal\/intranasal drug delivery","volume":"34","author":"Cunha","year":"2017","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0690","article-title":"Non-invasive strategies for nose-to-brain drug delivery","volume":"10","author":"Trevino","year":"2020","journal-title":"J. Clin. Trials"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0695","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0700","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0705","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10717544.2013.822945","article-title":"Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood","volume":"20","author":"Alam","year":"2013","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0710","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10717544.2014.885999","article-title":"Optimization of artemether-loaded NLC for intranasal delivery using central composite design","volume":"22","author":"Jain","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0715","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0720","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","article-title":"Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses","volume":"13","author":"Khan","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0725","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3109\/10717544.2014.975382","article-title":"Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study","volume":"23","author":"Madane","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0730","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1039\/C5RA19793G","article-title":"Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment","volume":"6","author":"Singh","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0735","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/21691401.2016.1160407","article-title":"Development and characterization of embelin-loaded nanolipid carriers for brain targeting","volume":"45","author":"Sharma","year":"2017","journal-title":"Artif. Cells, Nanomedicine, Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0740","article-title":"Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders","volume":"12","author":"Bahadur","year":"2020","journal-title":"Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0745","first-page":"337","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Fur Pharm. Verfahrenstechnik e.V."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0750","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.surneu.2003.09.036","article-title":"Introduction to nanotechnology and its applications to medicine","volume":"61","author":"Silva","year":"2004","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2021.05.001","article-title":"Human serum albumin as multifunctional nanocarrier for cancer therapy","author":"Zeeshan","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0760","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/0974-2077.63301","article-title":"Nanotechnology: the future medicine","volume":"3","author":"Saini","year":"2010","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0765","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003088-200645100-00002","article-title":"Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs","volume":"45","author":"Parveen","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112441","article-title":"Surface engineered nanocarriers for the management of breast cancer","volume":"130","author":"Nitheesh","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0775","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ces.2014.08.046","article-title":"Controlled drug release from pharmaceutical nanocarriers","volume":"125","author":"Lee","year":"2015","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0780","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2174\/1389201015666140508122558","article-title":"Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges","volume":"14","author":"Gidwani","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0785","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2174\/1381612821666150531164124","article-title":"Emerging use of nanotechnology in the treatment of neurological disorders","volume":"21","author":"Chhabra","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106491","article-title":"Development and validation of RP-HPLC method for quantification of repaglinide in mPEG-PCL polymeric nanoparticles: QbD-driven optimization, force degradation study, and assessment of in vitro release mathematic modeling","volume":"168","author":"Wadhwa","year":"2021","journal-title":"Microchem. J."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0795","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12951-018-0403-9","article-title":"Recent advancements in the use of exosomes as drug delivery systems","volume":"16","author":"Bunggulawa","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0800","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1073\/pnas.1418494112","article-title":"Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance","volume":"112","author":"Wei","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0805","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0810","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","article-title":"Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases","volume":"262","author":"Rufino-Ramos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0815","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1039\/D0TB02957B","article-title":"Recent advances in the design of inorganic and nano-clay particles for the treatment of brain disorders","volume":"9","author":"Persano","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0820","doi-asserted-by":"crossref","DOI":"10.1186\/s11671-019-3138-0","article-title":"Protoporphyrin IX-loaded laminarin nanoparticles for anticancer treatment, their cellular behavior, ROS detection, and animal studies","volume":"14","author":"Yu","year":"2019","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0825","series-title":"Green Nano-materials with Examples of Applications","author":"Bozoglu","year":"2015"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0830","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnsys.2018.00012","article-title":"Interfacing Graphene-Based Materials With Neural Cells","volume":"12","author":"Bramini","year":"2018","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0835","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2217\/nnm-2019-0367","article-title":"Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers","volume":"15","author":"Mulvihill","year":"2020","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0840","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1871527317666181004155136","article-title":"Epigenetics in neurodegenerative diseases: the role of histone deacetylases","volume":"18","author":"Sharma","year":"2019","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0845","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.2147\/IJN.S87148","article-title":"Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Fonseca-Santos","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0850","first-page":"249","article-title":"When poor solubility becomes an issue: from early stage to proof of concept","volume":"31","author":"Stegemann","year":"2007","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0855","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.2147\/IJN.S267007","article-title":"In vivo bio-distribution and toxicity evaluation of polymeric and lipid-based nanoparticles: a potential approach for chronic diseases treatment","volume":"15","author":"Fonseca-Gomes","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0860","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0865","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111837","article-title":"PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy","volume":"204","author":"Surekha","year":"2021","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0875","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.drudis.2012.05.003","article-title":"Carbon nanotube exploration in cancer cell lines","volume":"17","author":"Kesharwani","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0880","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.msec.2019.04.005","article-title":"Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology","volume":"101","author":"Choudhury","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2015.05.004","article-title":"Validating the anticancer potential of carbon nanotube-based therapeutics through cell line testing","author":"Kesharwani","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0890","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijpharm.2019.05.042","article-title":"Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting","volume":"565","author":"Choudhury","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0895","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jddst.2017.08.005","article-title":"Fabrication and characterization of nifedipine loaded \u03b2-cyclodextrin nanosponges: An in vitro and in vivo evaluation","volume":"41","author":"Shringirishi","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0900","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0905","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201701921","article-title":"Drug delivery to the brain across the blood-brain barrier using nanomaterials","volume":"13","author":"Tsou","year":"2017","journal-title":"Small."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0910","article-title":"Multivesicular liposome: A lipid-based drug delivery system for efficient drug delivery","volume":"27","author":"G. B, A.-D. BE, N. A, K. P, P. M, C. H","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0915","doi-asserted-by":"crossref","first-page":"19151","DOI":"10.1007\/s11356-019-05211-0","article-title":"Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery","volume":"27","author":"Zahin","year":"2020","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0920","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/jphp.13132","article-title":"Advancements in nanotherapeutics for Alzheimer\u2019s disease: current perspectives","volume":"71","author":"Harilal","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0925","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0930","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/acs.molpharmaceut.0c00461","article-title":"Design and validation of liposomal ApoE2 gene delivery system to evade blood-brain barrier for effective treatment of Alzheimer\u2019s disease","volume":"18","author":"Arora","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0935","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nano.2014.09.015","article-title":"Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-\u03b2 levels in APP\/PS1 transgenic mice","volume":"11","author":"Ord\u00f3\u00f1ez-Guti\u00e9rrez","year":"2015","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0940","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0945","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0950","doi-asserted-by":"crossref","DOI":"10.1051\/e3sconf\/202018504068","article-title":"Advance on the nano delivery system of curcumin","volume":"185","author":"Tang","year":"2020","journal-title":"E3S Web Conf."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2015.06.027","article-title":"Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin","author":"Jain","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0960","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcis.2016.07.020","article-title":"Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles","volume":"481","author":"Soni","year":"2016","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.614290","article-title":"Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy","volume":"11","author":"Bhagwat","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0970","series-title":"A.K. Mitra, K. Cholkar, A.B.T.-E.N. for D. Mandal Drug Delivery and Medical Devices (Eds.), Micro Nano Technol","first-page":"291","article-title":"Chapter 12 - Solid lipid nanoparticles in drug delivery: opportunities and challenges","author":"Deshpande","year":"2017"},{"key":"10.1016\/j.jconrel.2022.01.044_bb0975","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40005-013-0087-y","article-title":"Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery","volume":"43","author":"Yoon","year":"2013","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0980","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17425247.2016.1178237","article-title":"Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases","volume":"13","author":"Cacciatore","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0985","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0990","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12017-019-08524-y","article-title":"The Promises and challenges of erythropoietin for treatment of Alzheimer\u2019s disease","volume":"21","author":"Sun","year":"2019","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.jconrel.2022.01.044_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.nlm.2019.107082","article-title":"Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles","volume":"166","author":"Dara","year":"2019","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1000","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/1061186X.2012.747529","article-title":"Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer\u2019s disease model","volume":"21","author":"Yusuf","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.110948","article-title":"Deciphering the anti-apoptotic potential of \u03b1-bisabolol loaded solid lipid nanoparticles against A\u03b2 induced neurotoxicity in Neuro-2a cells","volume":"190","author":"Sathya","year":"2020","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1010","series-title":"Nanobiomaterials Galen. Formul. Cosmet","first-page":"297","article-title":"The role of liposomes and lipid nanoparticles in the skin hydration","author":"Estanqueiro","year":"2016"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1015","first-page":"123","article-title":"Nanoemulsion: an advanced mode of drug delivery system, 3","volume":"5","author":"Jaiswal","year":"2015","journal-title":"Biotech."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijpharm.2005.08.022","article-title":"The novel formulation design of O\/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds","volume":"305","author":"Araya","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1030","article-title":"Formulations of curcumin nanoparticles for brain diseases","volume":"9","author":"Del Prado-Audelo","year":"2019","journal-title":"Biomol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2020.117394","article-title":"Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer\u2019s, Parkinson\u2019s and Prion\u2019s","volume":"245","author":"Nirale","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1040","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuint.2012.07.025","article-title":"Naringenin ameliorates Alzheimer\u2019s disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model","volume":"61","author":"Khan","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ijbiomac.2018.06.190","article-title":"In vitro neuroprotective effects of naringenin nanoemulsion against \u03b2-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation","volume":"118","author":"Md","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1050","first-page":"87","article-title":"Aluminium and the pathogenesis of Alzheimer\u2019s disease: a summary of evidence, in","author":"McLachlan","year":"1992","journal-title":"CIBA Found. Symp."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/acsomega.0c05033","article-title":"Optimization of surfactant-and cosurfactant-aided pine oil nanoemulsions by isothermal low-energy methods for anticholinesterase activity","volume":"6","author":"Handa","year":"2020","journal-title":"ACS Omega."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1060","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2174\/1381612826666200317140600","article-title":"Therapeutic nanoemulsion: concept to delivery","volume":"26","author":"Barkat","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.07.020","article-title":"Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer\u2019s disease","author":"Handa","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1070","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zielinska","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijbiomac.2019.02.156","article-title":"Nanoparticle formulations in the diagnosis and therapy of Alzheimer\u2019s disease","volume":"130","author":"Gupta","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1080","first-page":"1","article-title":"Formulation development, optimization, and in vitro assessment of thermoresponsive ophthalmic pluronic F127-chitosan in situ tacrolimus gel","author":"Modi","year":"2021","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1085","doi-asserted-by":"crossref","first-page":"43629","DOI":"10.1039\/D0RA07640F","article-title":"Formulation development,: in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin","volume":"10","author":"Rathore","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jconrel.2021.12.012","article-title":"Chitosan: a versatile bio-platform for breast cancer theranostics","volume":"341","author":"Madamsetty","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1100","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1105","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.progpolymsci.2007.05.017","article-title":"Biodegradable polymers as biomaterials","volume":"32","author":"Nair","year":"2007","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","article-title":"Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model","volume":"14","author":"Carradori","year":"2018","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.colsurfb.2016.08.052","article-title":"Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer\u2019s disease","volume":"148","author":"Sun","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.8.1.9","article-title":"Galantamine in Alzheimer\u2019s disease","volume":"8","author":"Razay","year":"2008","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030227","article-title":"Hierarchical porous carbon-PLLA and PLGA hybrid nanoparticles for intranasal delivery of galantamine for Alzheimer\u2019s disease therapy","volume":"12","author":"Nanaki","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1130","article-title":"Dendrimer: a novel drug delivery system","volume":"1","author":"M. I","year":"2011","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1135","doi-asserted-by":"crossref","first-page":"8844030","DOI":"10.1155\/2021\/8844030","article-title":"Dendrimers: a new race of pharmaceutical nanocarriers","author":"Mittal","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2021.110746","article-title":"An insight into aptamer engineered dendrimer for cancer therapy","volume":"159","author":"Sheikh","year":"2021","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2021.110683","article-title":"Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery","volume":"158","author":"Singh","year":"2021","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1150","series-title":"Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics","first-page":"1","author":"Singh","year":"2021"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105890","article-title":"Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer","volume":"164","author":"Dubey","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.progpolymsci.2013.07.005","article-title":"Dendrimer as nanocarrier for drug delivery","volume":"39","author":"Kesharwani","year":"2014","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1170","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2021.08.003","article-title":"Advanced nanomedicine approaches applied for treatment of skin carcinoma","volume":"10","author":"Kaur","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1175","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mattod.2015.06.003","article-title":"PAMAM dendrimers as promising nanocarriers for RNAi therapeutics","volume":"18","author":"Kesharwani","year":"2015","journal-title":"Mater. Today"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2021.10.028","article-title":"RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy","volume":"340","author":"Sheikh","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1185","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2174\/1389201019666180226152542","article-title":"A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering siRNA to Neurons for Alzheimer\u2019s Disease Treatment","volume":"18","author":"Zhang","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1190","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1021\/acsomega.8b03445","article-title":"Dendrimer donepezil conjugates for improved brain delivery and better in vivo pharmacokinetics","volume":"4","author":"Singh","year":"2019","journal-title":"ACS Omega."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1195","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12249-020-01652-w","article-title":"Combined Therapy for Alzheimer\u2019s Disease: Tacrine and PAMAM Dendrimers Co-Administration Reduces the Side Effects of the Drug without Modifying its Activity","volume":"21","author":"Igart\u00faa","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1200","doi-asserted-by":"crossref","first-page":"176","DOI":"10.26452\/ijrps.v11i1.1804","article-title":"Recent developments in nano micelles as drug delivery system","volume":"11","author":"Mallya","year":"2020","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1205","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fnins.2020.00494","article-title":"Nanotechnology: a promising approach for delivery of neuroprotective drugs","volume":"14","author":"Naqvi","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4155\/tde.12.122","article-title":"Nanomicelles: an emerging platform for drug delivery to the eye","volume":"4","author":"Vadlapudi","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1215","first-page":"42","article-title":"Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior & posterior segments of the eye","volume":"10","author":"Velagaleti","year":"2010","journal-title":"Drug Deliv. Technol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1220","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.2147\/IJN.S258311","article-title":"PEG-ceramide nanomicelles induce autophagy and degrade Tau proteins in N2a cells","volume":"15","author":"Gao","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1225","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acsnano.9b09991","article-title":"Dual-sensitive nanomicelles enhancing systemic delivery of therapeutically active antibodies specifically into the brain","volume":"14","author":"Xie","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1230","doi-asserted-by":"crossref","DOI":"10.1002\/anie.200900441","article-title":"Nanogels as pharmaceutical carriers: finite networks of infinite capabilities","author":"Kabanov","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1235","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4155\/tde-2019-0010","article-title":"Nanogels as drug-delivery systems: a comprehensive overview","volume":"10","author":"Suhail","year":"2019","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1240","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jps.22395","article-title":"Encapsulation of valproate-loaded hydrogel nanoparticles in intact human erythrocytes: a novel nano-cell composite for drug delivery","volume":"100","author":"Hamidi","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1245","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/ma3021420","article-title":"Self-assembled hydrogel nanoparticles for drug delivery applications","volume":"3","author":"Gon\u00e7alves","year":"2010","journal-title":"Materials (Basel)."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1250","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2017.09.019","article-title":"Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP\/PS1 mice","volume":"1677","author":"Zhang","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1255","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.33263\/BRIAC106.71067119","article-title":"New candidate delivery system for Alzheimer\u2019s disease: deferoxamine nanogels","volume":"10","author":"Ashrafi","year":"2020","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2017.11.040","article-title":"Nose-to-brain delivery of insulin enhanced by a nanogel carrier","volume":"270","author":"Picone","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1265","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1038\/s41598-018-21933-6","article-title":"Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid \u03b2-protein aggregation and cytotoxicity","volume":"8","author":"Jiang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphotochemrev.2018.08.001","article-title":"Current status and prospects on chemical structure driven photoluminescence behaviour of carbon dots","volume":"37","author":"Barman","year":"2018","journal-title":"J Photochem Photobiol C: Photochem Rev"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1275","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/bio.3801","article-title":"Highly fluorescent carbon dots from wheat bran as a novel drug delivery system for bacterial inhibition","volume":"35","author":"Sunil John","year":"2020","journal-title":"Luminescence."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1280","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1021\/acsnano.6b00043","article-title":"Charge-convertible carbon dots for imaging-guided drug delivery with enhanced in vivo cancer therapeutic efficiency","volume":"10","author":"Feng","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1285","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.2147\/IJN.S318732","article-title":"Carbon dots: a future blood-brain barrier penetrating nanomedicine and drug nanocarrier","volume":"16","author":"Zhang","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1290","doi-asserted-by":"crossref","first-page":"19060","DOI":"10.1039\/C5NR06282A","article-title":"Graphene quantum dots for the inhibition of \u03b2 amyloid aggregation","volume":"7","author":"Liu","year":"2015","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1295","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.614906","article-title":"A novel nanosystem realizing curcumin delivery based on Fe(3)O(4)@Carbon dots nanocomposite for Alzheimer\u2019s disease therapy","volume":"8","author":"Kuang","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1300","doi-asserted-by":"crossref","DOI":"10.1007\/s11468-020-01338-w","article-title":"Fluorescence resonance energy transfer (FRET)-based ThT free sensing of beta-amyloid fibrillation by carbon dot-Ag composites","volume":"16","author":"Nair","year":"2021","journal-title":"Plasmonics."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1305","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1039\/C1NR11188D","article-title":"Gold nanoparticles: preparation, properties, and applications in bionanotechnology","volume":"4","author":"Yeh","year":"2012","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1310","series-title":"Nanobiotechnology in Neurodegenerative Diseases","author":"Rai","year":"2019"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1315","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1021\/acs.jpcc.7b05169","article-title":"Gold nanoparticles as a probe for amyloid-\u03b2 oligomer and amyloid formation","volume":"121","author":"Elbassal","year":"2017","journal-title":"J. Phys. Chem. C. Nanomater. Interfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.msec.2017.03.283","article-title":"Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer\u2019s type","volume":"77","author":"Muller","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1325","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbadis.2011.10.003","article-title":"Elevation of glutathione as a therapeutic strategy in Alzheimer disease","volume":"1822","author":"Pocernich","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1330","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","article-title":"Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"11","author":"Hou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1335","article-title":"Cerium oxide nanoparticles: a brief review of their synthesis methods and biomedical applications","volume":"7","author":"Dhall","year":"2018","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1340","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/nnm-2016-0399","article-title":"Cerium oxide nanoparticles: a \u201cradical\u201d approach to neurodegenerative disease treatment","volume":"12","author":"Naz","year":"2017","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1345","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/157341309788185523","article-title":"Cerium oxide nanoparticles trigger neuronal survival in a human Alzheimer disease model by modulating BDNF pathway","volume":"5","author":"D\u2019Angelo","year":"2009","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1350","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1021\/acsnano.5b08045","article-title":"Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer\u2019s disease","volume":"10","author":"Kwon","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1355","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1360","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1365","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1370","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/NEN.0b013e318225038c","article-title":"Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid \u03b2 protein antibody-coated nanoparticles","volume":"70","author":"Poduslo","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1375","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1308345110","article-title":"Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium","volume":"110","author":"Kolhar","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1380","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/439389","article-title":"Antibody-conjugated nanoparticles for biomedical applications","volume":"2009","author":"Arruebo","year":"2009","journal-title":"J. Nanomater."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1385","doi-asserted-by":"crossref","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","article-title":"Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer\u2019s disease","volume":"4","author":"Sonawane","year":"2019","journal-title":"ACS Omega."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1390","article-title":"Exploring the neuroprotective potential of rosiglitazone embedded nanocarrier system on streptozotocin induced mice model of Alzheimer\u2019s disease","volume":"1\u201316","author":"Sarathlal","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1395","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acschemneuro.1c00022","article-title":"Neuroprotective efficacy of co-encapsulated rosiglitazone and vorinostat nanoparticle on streptozotocin induced mice model of Alzheimer disease","volume":"12","author":"Sarathlal","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1400","series-title":"Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery","author":"Krishna","year":"2019"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1405","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3109\/1061186X.2010.513712","article-title":"Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain","volume":"18","author":"Zensi","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2006.12.012","article-title":"Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain","volume":"118","author":"Kreuter","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-016-0177-x","article-title":"Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E","volume":"14","author":"Neves","year":"2016","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1420","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.nano.2013.12.001","article-title":"Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect A$\u03b2$ aggregation features and cross the blood--brain-barrier: implications for therapy of Alzheimer disease","volume":"10","author":"Bana","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1425","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.biomaterials.2011.02.044","article-title":"Angiopep-conjugated poly (ethylene glycol)-co-poly ($\\varepsilon$-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma","volume":"32","author":"Xin","year":"2011","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1430","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2018.09.012","article-title":"Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy","volume":"132","author":"Kadari","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1435","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biomaterials.2014.10.007","article-title":"Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles","volume":"37","author":"Ruan","year":"2015","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1440","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2217\/nnm-2017-0181","article-title":"others, Improving gold nanorod delivery to the central nervous system by conjugation to the shuttle Angiopep-2","volume":"12","author":"Velasco-Aguirre","year":"2017","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1445","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s11095-011-0624-1","article-title":"Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells","volume":"29","author":"Chang","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1450","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1211\/jpp.59.7.0004","article-title":"Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain","volume":"59","author":"Gupta","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1455","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1460","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1016\/j.biomaterials.2013.07.075","article-title":"Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment","volume":"34","author":"Cui","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1465","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/hum.2010.111","article-title":"others, Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats","volume":"22","author":"Zhao","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1470","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1039\/C4NR04853A","article-title":"Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors","volume":"7","author":"Dixit","year":"2015","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1475","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2018.06.013","article-title":"A nanoformulation for the preferential accumulation in adult neurogenic niches","volume":"284","author":"Pra\u00e7a","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1480","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1021\/bc050217o","article-title":"Development and brain delivery of chitosan- PEG nanoparticles functionalized with the monoclonal antibody OX26","volume":"16","author":"Aktacs","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1485","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer\u2019s disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1490","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s13346-017-0368-5","article-title":"Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes","volume":"7","author":"Gu","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1495","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.2147\/IJN.S84656","article-title":"Anti-transferrin receptor-modified amphotericin B-loaded PLA--PEG nanoparticles cure Candidal meningitis and reduce drug toxicity","volume":"10","author":"Tang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1500","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/jgm.1152","article-title":"Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson\u2019s disease with Trojan horse liposomes and a tyrosine hydroxylase promoter","volume":"10","author":"Xia","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1505","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1016\/j.biomaterials.2012.06.063","article-title":"Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor","volume":"33","author":"Prades","year":"2012","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1510","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2011.05.062","article-title":"Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson\u2019s disease","volume":"415","author":"Hu","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1515","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2010.03.007","article-title":"Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery","volume":"40","author":"Chen","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1520","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.colsurfb.2015.06.025","article-title":"A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer\u2019s disease","volume":"134","author":"Meng","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1525","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.15252\/emmm.201505413","article-title":"Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in H untington\u2019s disease mice","volume":"7","author":"Valenza","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1530","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/nnm.10.74","article-title":"Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide","volume":"5","author":"Guerrero","year":"2010","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1535","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1021\/acs.molpharmaceut.5b00446","article-title":"Exploiting bacterial pathways for BBB crossing with PLGA nanoparticles modified with a mutated form of diphtheria toxin (CRM197): in vivo experiments","volume":"12","author":"Tosi","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1540","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jconrel.2003.08.006","article-title":"Brain uptake of thiamine-coated nanoparticles","volume":"93","author":"Lockman","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082331","article-title":"Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)","volume":"9","author":"Gaillard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1550","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s11095-013-1025-4","article-title":"Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides","volume":"30","author":"Li","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032616","article-title":"Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer\u2019s disease","volume":"7","author":"Mathew","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1560","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.biomaterials.2012.09.047","article-title":"Brain-targeted delivery of protein using chitosan-and RVG peptide-conjugated, pluronic-based nano-carrier","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1565","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.biomaterials.2008.08.004","article-title":"TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs","volume":"29","author":"Rao","year":"2008","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1570","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ijpharm.2012.07.029","article-title":"Penetratin-functionalized PEG--PLA nanoparticles for brain drug delivery","volume":"436","author":"Xia","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1575","first-page":"1031","article-title":"In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain","volume":"7","author":"Tian","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1580","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.043","article-title":"Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier","volume":"295","author":"Lu","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1585","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","article-title":"Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain","volume":"31","author":"Wang","year":"2010","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1590","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00103-007-0385-5","article-title":"Gene therapy of SCID-X1","volume":"50","author":"Baum","year":"2007","journal-title":"Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1595","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1600","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","article-title":"Viral vectors for therapy of neurologic diseases","volume":"120","author":"Choudhury","year":"2017","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1605","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/02648725.2018.1523521","article-title":"Current viral-mediated gene transfer research for treatment of Alzheimer\u2019s disease","volume":"35","author":"Sasmita","year":"2019","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1610","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/sj.gt.3301893","article-title":"Lentiviruses in gene therapy clinical research","volume":"9","author":"Connolly","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1615","doi-asserted-by":"crossref","DOI":"10.3390\/v12101106","article-title":"Gene therapy applications of non-human lentiviral vectors","volume":"12","author":"Munis","year":"2020","journal-title":"Viruses."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1620","doi-asserted-by":"crossref","DOI":"10.1002\/alz.058695","article-title":"Fibroblast growth factor 21 and autophagy modulation ameliorates amyloid $\u03b2$-induced Alzheimer disease pathology in rats","volume":"17","author":"Taliyan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1625","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1111\/bph.14637","article-title":"Adeno-associated virus-based Alzheimer\u2019s disease mouse models and potential new therapeutic avenues","volume":"176","author":"Ittner","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1630","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson\u2019s disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1635","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.apsb.2011.09.002","article-title":"Nonionic surfactant vesicular systems for effective drug delivery\u2014an overview","volume":"1","author":"Kumar","year":"2011","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1640","doi-asserted-by":"crossref","first-page":"58","DOI":"10.29161\/PT.v6.i3.2018.58","article-title":"Niosomes as novel drug delivery system: review article","volume":"6","author":"Sharma","year":"2018","journal-title":"Pharma Tutor"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1645","article-title":"Niosomes: present scenario and future aspects","volume":"8","author":"K. D, K. S","year":"2018","journal-title":"JDDT."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1650","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1248\/bpb.34.945","article-title":"Niosomes: a controlled and novel drug delivery system","volume":"34","author":"Rajera","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1655","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.015","article-title":"Nano-niosomes as nanoscale drug delivery systems: an illustrated review","volume":"185","author":"Moghassemi","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1660","article-title":"Niosomes: a review on niosomal research in the last decade","volume":"56","author":"Bhardwaj","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1665","first-page":"104","article-title":"Formulation of rivastigmine niosomes for Alzheimer disease","volume":"1","author":"Raeisi Estabragh","year":"2018","journal-title":"Int. Pharm. Acta."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1670","first-page":"243","article-title":"Preparation and study of the inhibitory effect of nano-niosomes containing essential oil from artemisia absinthium on amyloid fibril formation","volume":"7","author":"Ansari","year":"2020","journal-title":"Nanomed. J."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1675","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1515\/chem-2020-0089","article-title":"Preparation of a novel ginkgolide B niosomal composite drug","volume":"18","author":"Zhou","year":"2020","journal-title":"Open Chem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1680","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1021184216308","article-title":"Dry powder precursors of cubic liquid crystalline nanoparticles (cubosomes)","volume":"4","author":"Spicer","year":"2002","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1685","first-page":"1","article-title":"Cubosomes: a novel approach for delivery of anticancer drugs","volume":"7","author":"Balata","year":"2016","journal-title":"Int. J. PharmTech Res."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1690","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.2147\/IJN.S87336","article-title":"Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer\u2019s disease: pharmaceutical, biological, and toxicological studies","volume":"10","author":"Elnaggar","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1695","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120467","article-title":"Extracellular vesicles: a bright star of nanomedicine","volume":"269","author":"Wu","year":"2021","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1700","doi-asserted-by":"crossref","first-page":"18725","DOI":"10.1039\/C5NR01172H","article-title":"Destruction of amyloid fibrils by graphene through penetration and extraction of peptides","volume":"7","author":"Yang","year":"2015","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1705","doi-asserted-by":"crossref","DOI":"10.3390\/inorganics9060043","article-title":"New trends in nanoclay-modified sensors","volume":"9","author":"Pav\u00f3n","year":"2021","journal-title":"Inorganics"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1710","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1208\/aapsj0902022","article-title":"Polymer-drug conjugates as modulators of cellular apoptosis","volume":"9","author":"Vicent","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1715","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0b013e31827de92b","article-title":"others, Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study","volume":"37","author":"Jeyapalan","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1720","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.biomaterials.2007.09.024","article-title":"The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain","volume":"29","author":"Huang","year":"2008","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1725","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2022.01.044_bb1730","article-title":"ANG1005: Development of a new Engineered Peptide Compound (EPiC) for the treatment of malignant glioma, Poster Present","author":"Drappatz","year":"2009","journal-title":"Neurosci"},{"key":"10.1016\/j.jconrel.2022.01.044_bb1735","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1021\/jm9016637","article-title":"New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration","volume":"53","author":"Ch\u00e9","year":"2010","journal-title":"J. Med. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:29:09Z","timestamp":1759163349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592200058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":343,"alternative-id":["S016836592200058X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.044","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}